2005
DOI: 10.1016/j.clim.2005.08.004
|View full text |Cite
|
Sign up to set email alerts
|

C-reactive protein: Ligands, receptors and role in inflammation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

14
421
4
14

Year Published

2006
2006
2019
2019

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 570 publications
(453 citation statements)
references
References 74 publications
14
421
4
14
Order By: Relevance
“…C-reactive protein (CRP), an acute phase protein, is produced mainly by hepatocytes as a response to inflammation [12]. Thus, the measurement of circulating serum CRP is an important monitor of inflammatory disease in clinical routine [13].…”
Section: Introductionmentioning
confidence: 99%
“…C-reactive protein (CRP), an acute phase protein, is produced mainly by hepatocytes as a response to inflammation [12]. Thus, the measurement of circulating serum CRP is an important monitor of inflammatory disease in clinical routine [13].…”
Section: Introductionmentioning
confidence: 99%
“…serum amyloid P component | CD89 | acute phase protein C -reactive protein (CRP), a member of the pentraxin family, is a major acute-phase protein in humans and is a clinical marker of infection (1). Interest in the biological activities of CRP has increased dramatically in recent years because of its association with inflammatory diseases such as atherosclerosis and autoimmune diseases such as systemic lupus erythematosus.…”
mentioning
confidence: 99%
“…Although the role of CRP in pathogen clearance through complement activation has been established (2), the participation of pentraxins in activating cellular immune functions is poorly understood because of a lack of knowledge of their cellular receptors. CRP and SAP have been shown to bind and activate Fcγ receptors (FcγR) on monocytes and macrophages (1,(3)(4)(5)(6). In addition, CRP suppressed immune complex-mediated nephrotoxic nephritis in a mouse model (7).…”
mentioning
confidence: 99%
“…It was recently reported that a similar proportion of ET patients with monoclonal XCIPs patterns could be found in JAK2 mutated and non-mutated patients. 5,6 However, in those studies, only HUMARA assay was performed to assess clonality, a methylation-based test that is not completely reliable for patients' samples analysis because of possible abnormal DNA methylation in malignancies. 7 We studied a series of female ET patients in whom XCIPs had previously been analyzed by our group using both gene methylation and expression assays in all hematopoietic cell lineages 1,2 for the presence of mutant JAK2 and tested if the mutation correlated with monoclonal phenotype that would be expected if JAK2 mutation plays a role in disease development.…”
mentioning
confidence: 99%